Log in
NASDAQ:GTXI

GTX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.66
+0.12 (+4.72 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.57
Now: $2.66
$2.74
50-Day Range
$1.20
MA: $4.77
$7.20
52-Week Range
$0.74
Now: $2.66
$25.60
Volume633,711 shs
Average Volume390,540 shs
Market Capitalization$63.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
GTX logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700
Employees21

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.09 per share

Profitability

Net Income$-38,420,000.00

Miscellaneous

Market Cap$63.97 million
Next Earnings DateN/A
OptionableOptionable

Receive GTXI News and Ratings via Email

Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GTX (NASDAQ:GTXI) Frequently Asked Questions

What stocks does MarketBeat like better than GTX?

Wall Street analysts have given GTX a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GTX wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) released its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09.
View GTX's earnings history
.

Who are some of GTX's key competitors?

What other stocks do shareholders of GTX own?

Who are GTX's key executives?

GTX's management team includes the following people:
  • Dr. Robert James Wills B.S., M.S., Ph.D., Exec. Chairman (Age 65)
  • Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)
  • Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)
  • Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)
  • Dr. Diane C. Young, VP & Chief Medical Officer (Age 62)

What is GTX's stock symbol?

GTX trades on the NASDAQ under the ticker symbol "GTXI."

What is GTX's stock price today?

One share of GTXI stock can currently be purchased for approximately $2.66.

How big of a company is GTX?

GTX has a market capitalization of $63.97 million. The biopharmaceutical company earns $-38,420,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. GTX employs 21 workers across the globe.

What is GTX's official website?

The official website for GTX is www.gtxinc.com.

How can I contact GTX?

GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.